Sign In

Praveen Tipirneni

CEO at Morphic Therapeutic

Praveen Tipirneni was the President and CEO of Morphic Therapeutic, a biotech company focused on developing oral integrin drugs.2 He led the company from its founding in 2015 until its recent acquisition by Eli Lilly for $3.2 billion.67

Tipirneni has an extensive background in the biotech and pharmaceutical industries:

  • Education: BS in Mechanical Engineering from MIT, MD from McGill University, and MBA in Healthcare Finance from Wharton School of Business.25
  • Previous roles: Senior Vice President of Corporate Development and Global Strategy at Cubist Pharmaceuticals (2002-2015).25
  • Military service: Served as a First Lieutenant in the U.S. Army.45

His career highlights include:

  • Leading Morphic Therapeutic's development of innovative oral integrin drugs.2
  • Contributing to the development of Cubicin, a flagship antibiotic, during his time at Cubist Pharmaceuticals.4
  • Publishing articles in major outlets like HuffPost and Forbes.2

As of February 2025, Tipirneni has transitioned to new roles:

  • Appointed as a non-executive director on the Board of BridgeBio Oncology Therapeutics (BBOT) in November 2024.6
  • Joined Atlas Venture as a Venture Partner.8

Tipirneni's LinkedIn profile (username: praveen-tipirneni-42a1a5) lists him as based in Boston, Massachusetts.13

Related Questions

What are the key achievements of Praveen Tipirneni at Morphic Therapeutic?
How did Praveen Tipirneni's background in corporate development influence his leadership at Morphic Therapeutic?
What are the main goals of Morphic Therapeutic under Praveen Tipirneni's leadership?
How has Praveen Tipirneni's career evolved from his early roles to his current position at Morphic Therapeutic?
What challenges has Praveen Tipirneni faced as the CEO of Morphic Therapeutic?
Praveen Tipirneni
Praveen Tipirneni, photo 1
Praveen Tipirneni, photo 2
Add to my network

Location

Boston, Massachusetts, United States